Last Monday Ecuador announced a new cooperation agreement to be signed with China, totalling $53 million, which will allow Chinese-made medicines and vaccines to be distributed in the South American country. The agreement was signed by State-owned laboratories Enfarma, represented by Luis Monteverde, and Cui Jiao of China’s Sinopharm. The agreement will also re-start a vaccine-manufacturing plant in the country.
“Today we have set out towards a new future of integral cooperation, not only in the supply and delivery of medicine and active ingredients, but also in investment, construction and operation of pharmaceutical factories” said Jiao.
Eduardo Egas, Ecuador’s Industry and Productivity Minister, has said that “It will add… 14 additional vaccines (to the eight already made within the country), which will really help in taking care of the people’s health, especially during times like these, when many illnesses are around.” Other South American countries such as Bolivia and Cuba have signed similar agreements since 2014, hoping to break their dependence on international monopolies.
Full content: Tn8
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Belgian Authorities Detain Multiple Individuals Over Alleged Huawei Bribery in EU Parliament
Mar 13, 2025 by
CPI
Grubhub’s Antitrust Case to Proceed in Federal Court, Second Circuit Rules
Mar 13, 2025 by
CPI
Pharma Giants Mallinckrodt and Endo to Merge in Multi-Billion-Dollar Deal
Mar 13, 2025 by
CPI
FTC Targets Meta’s Market Power, Calls Zuckerberg to Testify
Mar 13, 2025 by
CPI
French Watchdog Approves Carrefour’s Expansion, Orders Store Sell-Off
Mar 13, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Self-Preferencing
Feb 26, 2025 by
CPI
Platform Self-Preferencing: Focusing the Policy Debate
Feb 26, 2025 by
Michael Katz
Weaponized Opacity: Self-Preferencing in Digital Audience Measurement
Feb 26, 2025 by
Thomas Hoppner & Philipp Westerhoff
Self-Preferencing: An Economic Literature-Based Assessment Advocating a Case-By-Case Approach and Compliance Requirements
Feb 26, 2025 by
Patrice Bougette & Frederic Marty
Self-Preferencing in Adjacent Markets
Feb 26, 2025 by
Muxin Li